|
FOP: Enhancing Diagnosis and Management to Improve Patients’ Quality of Life
Target Audience
The educational design of this activity addresses the needs of the primary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, and genetic counselors, and the secondary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, and specialist NPs and PAs.
Program Overview
Because fibrodysplasia ossificans progressiva, or FOP, is exceedingly rare, even specialists... |
|
Dialogues about FOP: What Patients Wish More Doctors Knew to Enhance Early Recognition and Management
Target Audience
The educational design of this activity addresses the needs of the primary audience of PCPs, pediatricians, dermatologists, endocrinologists, occupational therapists, oncologists, general practice NPs and PAs, specialist NPs and PAs, and the secondary audience of orthopedists, bone specialists, rheumatologists, pediatric rheumatologists, genetic counselors, and dentists.
Statement of Need/Program Overview
Fibrodysplasia ossificans progressiva (FOP) causes abnormal bone for... |
|
Therapeutic Advancements for the Treatment of High-Risk MDS: Future Opportunities to Improve Patient Survival and Quality of Life
Stay up to date on the evolving risk classification for myelodysplastic syndromes (MDS) and current treatment guidelines for patients with high-risk disease in this self-directed education with leading oncology experts. Expert commentary from Courtney DiNardo, MD from MD Anderson Cancer Center and Dr. Dan Pollyea from the University of Colorado School of Medicine provides insights on emerging therapies that could soon improve management of high-risk MDS. Be ready to incorporate these emerging ... |